Gilead reports strong Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis
Gilead Sciences announced that in the Phase 3 IDEAL study, 75.4% of patients treated with Livdelzi achieved alkaline phosphatase (ALP) normalization at Week 52, compared with 16.1% on placebo. The benefit was already evident after one month, with 52.3% versus 6.5% achieving the endpoint. Serious adverse events occurred in 3.1% of the Livdelzi group versus 12.9% of placebo. Gilead will discuss the data with global regulators and present the findings at The Liver Meeting 2026.
Why it matters
The company said it will engage regulatory authorities, which could broaden Livdelzi’s approved use and affect GILD’s future revenue. The results may also influence investor sentiment toward Gilead’s pipeline.
Key facts
- 175.4% (49/65) of Livdelzi‑treated participants achieved ALP normalization at Week 52 versus 16.1% (5/31) on placebo. stocktitan.net
- 252.3% of Livdelzi‑treated participants achieved ALP normalization after one month versus 6.5% on placebo. investing.com
- 3Serious adverse events occurred in 3.1% of the Livdelzi group and 12.9% of the placebo group. investing.com
- 4The IDEAL study enrolled 96 adults aged 18‑75 with ALP levels between 1‑1.67× ULN. investing.com
- 5Results will be presented at The Liver Meeting 2026 in Denver, Colorado. stocktitan.net
- 6Gilead plans to engage global regulatory authorities to discuss the trial results. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.